Samarium-153
Citation, DOI, disclosures and article data
At the time the article was created Francesco Sciacca had no recorded disclosures.
View Francesco Sciacca's current disclosuresAt the time the article was last revised Arlene Campos had no financial relationships to ineligible companies to disclose.
View Arlene Campos's current disclosures- Samarium-153 EDTMP
- Sm-153 EDTMP
- Sm-153
Samarium-153 (Sm-153) is a radioisotope used in metabolic radiation therapy for the treatment of pain from bone metastases. It is produced in nuclear reactors, by neutron irradiation of samarium-152 (Sm-152 Sm2O3).
Samarium-153 decays by emitting both beta minus particles and gamma photons with a characteristic gamma peak of 103.2 KeV; it has a physical half-life time of 1.93 days. The carrier molecule used is the ethylene diamine tetramethylene phosphonate acid (EDTMP), a chelator osteotropic tetraphosphonate. The radiopharmaceutical Sm-153 EDTMP (dose: 37 MBq/Kg) shows a biodistribution similar to that of technetium-99m methylene diphosphonate (Tc-99m MDP). The gamma (photons) component also allows the use of the radiotracer for nuclear medical imaging (follow-up).
References
- 1. Serafini A. Systemic Metabolic Radiotherapy with Samarium-153 EDTMP for the Treatment of Painful Bone Metastasis. Q J Nucl Med. 2001;45(1):91-9. - Pubmed
- 2. Handkiewicz-Junak D, Poeppel T, Bodei L et al. EANM Guidelines for Radionuclide Therapy of Bone Metastases with Beta-Emitting Radionuclides. Eur J Nucl Med Mol Imaging. 2018;45(5):846-59. doi:10.1007/s00259-018-3947-x - Pubmed
- 3. Ishfaq M, Mushtaq A, Jawaid M. Experience on the Neutron Activation of Natural/Enriched Re, Sm, and Ho Nuclides in a Reactor for the Production of Radiotherapeutic Radionuclides. Biol Trace Elem Res. 1999;71-72(1):519-26. doi:10.1007/BF02784240 - Pubmed
- 4. Turner J & Claringbold P. A Phase II Study of Treatment of Painful Multifocal Skeletal Metastases with Single and Repeated Dose Samarium-153 Ethylenediaminetetramethylene Phosphonate. Eur J Cancer. 1991;27(9):1084-6. doi:10.1016/0277-5379(91)90297-q - Pubmed
- 5. Giuliano Mariani, Paola Anna Erba, Duccio Volterrani. Fondamenti Di Medicina Nucleare. (2015) ISBN: 9788847016842 - Google Books
Related articles: Imaging technology
- imaging technology
- imaging physics
- imaging in practice
-
x-rays
- x-ray physics
- x-ray in practice
- x-ray production
- x-ray tube
- filters
- automatic exposure control (AEC)
- beam collimators
- grids
- air gap technique
- cassette
- intensifying screen
- x-ray film
- image intensifier
- digital radiography
- digital image
- mammography
- x-ray artifacts
- radiation units
- radiation safety
- radiation detectors
- fluoroscopy
-
computed tomography (CT)
- CT physics
- CT in practice
- CT technology
- CT image reconstruction
- CT image quality
- CT dose
-
CT contrast media
-
iodinated contrast media
- agents
- water soluble
- water insoluble
- vicarious contrast material excretion
- iodinated contrast media adverse reactions
- agents
- non-iodinated contrast media
-
iodinated contrast media
-
CT artifacts
- patient-based artifacts
- physics-based artifacts
- hardware-based artifacts
- ring artifact
- tube arcing
- out of field artifact
- air bubble artifact
- helical and multichannel artifacts
- CT safety
- history of CT
-
MRI
- MRI physics
- MRI in practice
- MRI hardware
- signal processing
-
MRI pulse sequences (basics | abbreviations | parameters)
- T1 weighted image
- T2 weighted image
- proton density weighted image
- chemical exchange saturation transfer
- CSF flow studies
- diffusion weighted imaging (DWI)
- echo-planar pulse sequences
- fat-suppressed imaging sequences
- gradient echo sequences
- inversion recovery sequences
- metal artifact reduction sequence (MARS)
-
perfusion-weighted imaging
- techniques
- derived values
- saturation recovery sequences
- spin echo sequences
- spiral pulse sequences
- susceptibility-weighted imaging (SWI)
- T1 rho
- MR angiography (and venography)
-
MR spectroscopy (MRS)
- 2-hydroxyglutarate peak: resonates at 2.25 ppm
- alanine peak: resonates at 1.48 ppm
- choline peak: resonates at 3.2 ppm
- citrate peak: resonates at 2.6 ppm
- creatine peak: resonates at 3.0 ppm
- functional MRI (fMRI)
- gamma-aminobutyric acid (GABA) peak: resonates at 2.2-2.4 ppm
- glutamine-glutamate peak: resonates at 2.2-2.4 ppm
- Hunter's angle
- lactate peak: resonates at 1.3 ppm
- lipids peak: resonates at 1.3 ppm
- myoinositol peak: resonates at 3.5 ppm
- MR fingerprinting
- N-acetylaspartate (NAA) peak: resonates at 2.0 ppm
- propylene glycol peak: resonates at 1.13 ppm
-
MRI artifacts
- MRI hardware and room shielding
- MRI software
- patient and physiologic motion
- tissue heterogeneity and foreign bodies
- Fourier transform and Nyquist sampling theorem
- MRI contrast agents
- MRI safety
-
ultrasound
- ultrasound physics
-
transducers
- linear array
- convex array
- phased array
- frame averaging (frame persistence)
- ultrasound image resolution
- imaging modes and display
- pulse-echo imaging
- real-time imaging
-
Doppler imaging
- Doppler effect
- color Doppler
- power Doppler
- B flow
- color box
- Doppler angle
- pulse repetition frequency and scale
- wall filter
- color write priority
- packet size (dwell time)
- peak systolic velocity
- end-diastolic velocity
- resistive index
- pulsatility index
- Reynolds number
- panoramic imaging
- compound imaging
- harmonic imaging
- elastography
- scanning modes
- 2D ultrasound
- 3D ultrasound
- 4D ultrasound
- M-mode
-
ultrasound artifacts
- acoustic shadowing
- acoustic enhancement
- beam width artifact
- reverberation artifact
- ring down artifact
- mirror image artifact
- side lobe artifact
- speckle artifact
- speed displacement artifact
- refraction artifact
- multipath artifact
- anisotropy
- electrical interference artifact
- hardware-related artifacts
- Doppler artifacts
- aliasing
- tissue vibration
- spectral broadening
- blooming
- motion (flash) artifact
- twinkling artifact
- acoustic streaming
- biological effects of ultrasound
- history of ultrasound
-
nuclear medicine
- nuclear medicine physics
- detectors
- tissue to background ratio
-
radiopharmaceuticals
- fundamentals of radiopharmaceuticals
- radiopharmaceutical labeling
- radiopharmaceutical production
- nuclear reactor produced radionuclides
- cyclotron produced radionuclides
- radiation detection
- dosimetry
- specific agents
- carbon-11
- chromium-51
- fluorine agents
- gallium agents
- Ga-67 citrate
- Ga-68
- iodine agents
-
I-123
- I-123 iodide
- I-123 ioflupane (DaTSCAN)
- I-123 ortho-iodohippurate
- I-131
-
MIBG scans
- I-123 MIBG
- I-131 MIBG
-
I-123
- indium agents
- In-111 Octreoscan
- In-111 OncoScint
- In-111 Prostascint
- In-111 oxine labeled WBC
- krypton-81m
- nitrogen-13
- oxygen-15
- phosphorus-32
- selenium-75
-
technetium agents
- Tc-99m DMSA
- Tc-99m DTPA
- Tc-99m DTPA aerosol
- Tc-99m HMPAO
- Tc-99m HMPAO labeled WBC
- Tc-99m MAA
- Tc-99m MAG3
- Tc-99m MDP
- Tc-99m mercaptoacetyltriglycine
- Tc-99m pertechnetate
- Tc-99m labeled RBC
- Tc-99m sestamibi
- Tc-99m sulfur colloid
- Tc-99m sulfur colloid (oral)
- thallium-201 chloride
- xenon agents
- in vivo therapeutic agents
- pharmaceuticals used in nuclear medicine
-
emerging methods in medical imaging
- radiography
- phase-contrast imaging
- CT
- deep-learning reconstruction
- photon counting CT
- virtual non-contrast imaging
- ultrasound
- magnetomotive ultrasound (MMUS)
- superb microvascular imaging
- ultrafast Doppler imaging
- ultrasound localization microscopy
- MRI
- nuclear medicine
- total body PET system
- immuno-PET
- miscellaneous
- radiography